Leukemia Home > Clolar and Breastfeeding
The manufacturer of Clolar (clofarabine) generally recommends that women stop breastfeeding during treatment. Although no studies have been done to determine if this drug passes through breast milk or if it would harm a nursing infant, potentially dangerous side effects are possible, which may pose a risk to a baby whose mother uses Clolar while breastfeeding.
Clolar® (clofarabine) is a prescription chemotherapy medication used to treat children and young adults with acute lymphoblastic leukemia, a type of blood cancer. At this time, it is unknown if Clolar passes through breast milk. The manufacturer advises that women avoid breastfeeding during treatment.
Clolar has not been studied in breastfeeding women. Therefore, it is unknown if the drug passes through breast milk, or if it would harm a nursing infant. It should be noted that medications are rarely studied in breastfeeding women, as doing so would usually expose an infant, who will not directly benefit from the drug, to possible risks.
Many medicines pass through breast milk. Based on the properties of Clolar, it is expected to pass through breast milk to some extent.
Clolar is associated with potentially serious side effects. Because these might occur in a nursing infant, it is generally recommended that women not breastfeed while receiving Clolar.
You should discuss breastfeeding and Clolar use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.